QuidelOrtho Corporation reported total revenue of $614 million for the second quarter of 2025, compared to $637 million in the prior year period, primarily due to lower COVID-19 and Donor Screening revenue. Despite the overall revenue decrease, Labs revenue grew 4% as reported and 5% in constant currency.
The company achieved an adjusted diluted EPS of $0.12, a significant improvement from an adjusted diluted loss per share of ($0.07) in the prior year period. Adjusted EBITDA for the quarter was $107 million, up from $90 million in the prior year, with the adjusted EBITDA margin improving by 330 basis points to 17%.
QuidelOrtho announced it achieved $100 million in annualized cost savings from initiatives announced in 2024 and reiterated its full-year 2025 financial guidance. The second quarter results included $179 million in restructuring, integration, and other charges, with $150 million related to the discontinuation of the Savanna platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.